This extensive clinical development initiative aims to assess the effectiveness and safety of datopotamab deruxtecan, either as a monotherapy or in combination with other antitumor agents, specifically targeting Trop2+ NSCLC (11). Here, TACSTD2 is linked to non-small cell lung carcinoma.